Myeloma Minute: Why Prevention Matters


| INNOVATION | Latest Research


Why Prevention Matters

Curing multiple myeloma is a goal we all share. The IMF’s Black Swan Research Initiative® is engaged in dozens of studies around the world aimed at just that. But in the meantime, more and more research suggests we might prevent myeloma by limiting our exposure to cancer-triggering toxins.


| Action | Baseball for Myeloma


Multiple Myeloma Survivor to Throw Out First Pitch at Sept. 16 Houston Astros Game

Michael Tuohy, an eighteen-year myeloma survivor, will throw the ceremonial first pitch at the Houston Astros baseball game on September 16. Michael will represent the International Myeloma Foundation (IMF), the first and largest foundation focusing specifically on multiple myeloma. Sponsored by Amgen Oncology, this game at Houston’s Minute Maid Park will raise awareness of myeloma and encourage patients to create a personal treatment management strategy. Through its newly launched Myeloma MVP (Most Valuable Plan) program, Amgen is connecting myeloma patients with management guidance tools and educational resources, including the comprehensive IMF website.


| INSPIRATION | Fundraiser




Sixth Annual Miracles for Myeloma 5K Race/Walk
Register NOW for a Regional Community Workshop in Birmingham, Alabama

The Sixth Annual Miracles for Myeloma 5K Race/Walk takes place on Saturday, September 22, 2018, beginning at 9:30 a.m. EST on a USATF-certified course in Oak Ridge Park, New Jersey. Registration ends on September 18 at midnight. Donations can be made until December, whether or not you are able to participate. Last year’s Miracles for Myeloma raised nearly $80,000 for myeloma research, funding a Senior Brian D. Novis Research Grant. Once again, we encourage you to help raise myeloma awareness and funds as we work toward a cure.

The IMF will conduct a Regional Community Workshop in Birmingham, AL, on Saturday, October 6, 2018. Registration is FREE, but seating is limited. This is a wonderful opportunity to learn from and meet one-on-one with myeloma experts Luciano J. Costa, MD, PhD (Associate Professor of Medicine, University of Alabama at Birmingham), Kelly Godby, MD (Assistant Professor of Medicine, UAB Hematology/Oncology, University of Alabama at Birmingham), and Charise Gleason, MSN, NP-BC, AOCNP (Winship Cancer Institute, Emory University, Atlanta).


Register Now Button.png

| INNOVATION | Drug Development


Empliciti (elotuzumab) Drug Combination Granted Priority Review by FDA

Bristol-Myers Squibb has announced that the FDA accepted its supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma who have received at least two prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor. The FDA granted the application priority review with an action date of December 27, 2018. This sBLA was submitted based on the phase II ELOQUENT-3 trial.


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



BOSTON Trial Fact Sheet

New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

September 8, 2018
IMF Regional Community Workshop
Richmond, VA

September 15, 2018
IMF Regional Community Workshop
Columbus, OH

September 22, 2018
6th Annual Miracles for Myeloma 5K Race/Walk
Oak Ridge Park Clark, NJ

September 22, 2018
IMF Regional Community Workshop
Overland Park, KS

September 22, 2018
A Mission for Matt
Mineola, NY

October 12-13, 2018
IMF Patient & Family Seminar
Philadelphia, PA

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.